Grabner Alexander, Kentrup Dominik, Schnöckel Uta, Gabriëls Gert, Schröter Rita, Pavenstädt Hermann, Schober Otmar, Schlatter Eberhard, Schäfers Michael, Reuter Stefan
Department of Internal Medicine D, Experimental Nephrology, University of Münster.
J Vis Exp. 2013 Apr 28(74):e4240. doi: 10.3791/4240.
The number of patients with end-stage renal disease, and the number of kidney allograft recipients continuously increases. Episodes of acute cellular allograft rejection (AR) are a negative prognostic factor for long-term allograft survival, and its timely diagnosis is crucial for allograft function (1). At present, AR can only be definitely diagnosed by core-needle biopsy, which, as an invasive method, bares significant risk of graft injury or even loss. Moreover, biopsies are not feasible in patients taking anticoagulant drugs and the limited sampling site of this technique may result in false negative results if the AR is focal or patchy. As a consequence, this gave rise to an ongoing search for new AR detection methods, which often has to be done in animals including the use of various transplantation models. Since the early 60s rat renal transplantation is a well-established experimental method for the examination and analysis of AR (2). We herein present in addition small animal positron emission tomography (PET) using (18)F-fluorodeoxyglucose (FDG) to assess AR in an allogeneic uninephrectomized rat renal transplantation model and propose graft FDG-PET imaging as a new option for a non-invasive, specific and early diagnosis of AR also for the human situation (3). Further, this method can be applied for follow-up to improve monitoring of transplant rejection (4).
终末期肾病患者数量以及肾移植受者数量持续增加。急性细胞移植排斥反应(AR)发作是移植肾长期存活的负面预后因素,其及时诊断对于移植肾功能至关重要(1)。目前,AR仅能通过粗针活检明确诊断,而粗针活检作为一种侵入性方法,具有移植肾损伤甚至丧失的重大风险。此外,活检对于正在服用抗凝药物的患者不可行,并且如果AR是局灶性或斑片状的,该技术有限的取材部位可能导致假阴性结果。因此,这引发了对新的AR检测方法的持续探索,这通常需要在动物身上进行,包括使用各种移植模型。自20世纪60年代初以来,大鼠肾移植是用于检查和分析AR的成熟实验方法(2)。我们在此还介绍了使用(18)F-氟脱氧葡萄糖(FDG)的小动物正电子发射断层扫描(PET),以评估同种异体单肾切除大鼠肾移植模型中的AR,并提出移植肾FDG-PET成像作为一种非侵入性、特异性且早期诊断AR的新选择,同样适用于人类情况(3)。此外,该方法可用于随访,以改善对移植排斥反应的监测(4)。